AAV has become one of the leading vector platforms for gene therapy, gene editing, and in vivo gene delivery. However, achieving high vector yields while maintaining excellent vector quality remains a major challenge in AAV manufacturing. Production efficiency can vary significantly depending on the AAV serotype, transgene, producer cell line, transfection reagent, and culture conditions, often resulting in increased manufacturing costs and limited scalability.

AAV production enhancers are specialized cell culture supplements or small molecules designed to improve AAV manufacturing by optimizing the cellular environment during vector production. These reagents enhance key biological processes involved in AAV production, including transgene expression, vector genome replication, capsid protein synthesis, capsid assembly, and genome packaging. The result is increased vector productivity while preserving critical quality attributes such as vector genome integrity, infectivity, and the full-to-empty capsid ratio.

An ideal AAV production enhancer should provide:

• Significant improvement in AAV vector yield
• Broad compatibility with multiple AAV serotypes and transgene constructs
• Compatibility with HEK293-derived producer cell lines and standard transfection reagents
• Easy integration into existing production workflows without additional process optimization
• Preservation or improvement of vector quality, including full capsid packaging efficiency and infectivity
• Consistent performance from laboratory-scale production to large-scale bioreactor manufacturing

As the demand for high-quality AAV vectors continues to grow, AAV production enhancers have become an important tool for increasing manufacturing efficiency, reducing production costs, and accelerating the development and commercialization of gene therapies.